In support of this notion, afatinib reversed ABCB1-mediated multidrug resistance in ABCB1-overexpressing ovarian cancer cells by inhibiting the efflux function of ABCB1 [25] and GW8510, a cyclin-dependent kinase inhibitor, inhibited RRM2 expression through promoting its proteasomal degradation [26]. This evidence concerns the gene ABCB1 and ovarian cancer.